Combinatorial approach to treatment of melanoma
- PMID: 24880950
- DOI: 10.1016/j.hoc.2014.03.002
Combinatorial approach to treatment of melanoma
Abstract
There are multiple effective and well-tolerated systemic therapy treatments for the treatment of advanced melanoma, as well as new immunotherapy and targeted therapy agents in clinical trials. Traditional cytotoxic chemotherapy and targeted BRAF inhibitors can increase antigen presentation and can rebalance the intratumoral immune milieu. The combination of pulsed cytotoxic therapy and immunotherapy is a logical next step in designing treatment regimens. Combination radiotherapy and immunotherapy also has experimental and clinical support. The standard of care for patients with advanced melanoma remains participation in clinical trials in order to enhance understanding of the effectiveness and toxicities of combination regimens.
Keywords: BRAF; Combination therapy; Immunotherapy; Melanoma; Mitogen-activated extracellular kinase; Targeted therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Indications and options for systemic therapy in melanoma.Surg Clin North Am. 2014 Oct;94(5):1049-58, viii. doi: 10.1016/j.suc.2014.07.007. Epub 2014 Aug 6. Surg Clin North Am. 2014. PMID: 25245967 Review.
-
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy.Arch Dermatol Res. 2014 Aug;306(6):521-6. doi: 10.1007/s00403-014-1462-x. Epub 2014 Mar 30. Arch Dermatol Res. 2014. PMID: 24682537 Review.
-
Melanoma: from darkness to promise.Am J Clin Oncol. 2011 Apr;34(2):179-87. doi: 10.1097/COC.0b013e3181d6b427. Am J Clin Oncol. 2011. PMID: 20498590 Review.
-
Medical management of melanoma.Surg Clin North Am. 2003 Apr;83(2):283-322, viii. doi: 10.1016/S0039-6109(02)00187-1. Surg Clin North Am. 2003. PMID: 12744611 Review.
-
Novel therapeutics for the treatment of metastatic melanoma.Future Oncol. 2009 May;5(4):543-57. doi: 10.2217/fon.09.15. Future Oncol. 2009. PMID: 19450181 Review.
Cited by
-
Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma.Vet Sci. 2023 Mar 26;10(4):249. doi: 10.3390/vetsci10040249. Vet Sci. 2023. PMID: 37104404 Free PMC article.
-
Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.Lab Invest. 2017 Feb;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24. Lab Invest. 2017. PMID: 27775691
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials